Search

Displaying results 1271 - 1280 of 2816 in total
  1. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  2. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    This medication is known to target Glutathione S-transferase P. Ezatiostat is a small molecule drug that is an analog inhibitor of glutathione S-transferase P1-1.

  3. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

    Mixtures: NELLCO SPECIAL OBH PE
  4. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  5. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 ...

    Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersSynonyms: (−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
  7. Drug

    Fluticasone propionate

    go.drugbank.com/drugs/DB00588
    ApprovedInvestigational

    Fluticasone propionate is a synthetic glucocorticoid [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. Fluticasone propionate was first approved in...

    Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Enprofylline

    go.drugbank.com/drugs/DB00824
    ApprovedWithdrawn

    Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and ...

    Categories: Purinergic P1 Receptor Antagonists
  9. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

    Categories: Purinergic P1 Receptor Agonists
  10. Drug

    Epinephrine

    go.drugbank.com/drugs/DB00668
    ApprovedInvestigationalVet approved

    On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths [L4353].

    Mixtures: Blue Gel AnestheticCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors